

1 **Zinc Oxide: Development of novel products for weaned piglets**

2

3 Marina Sígolo Rodrigues Barreto^{a,b}, Carlos Adam Conte-Junior^{a,b,c,*}

4

5 ^a Department of Food Technology, Faculty of Veterinary Medicine, University Federal
6 Fluminense. CEP: 24230-340, Niterói, Brazil.

7 ^b Food Science Program, Instituto de Química, Universidade Federal do Rio de Janeiro. CEP:
8 21941-909, Rio de Janeiro, Brazil.

9 ^c National Institute of Health Quality Control, Fundação Oswaldo Cruz. CEP: 21040-900, Rio
10 de Janeiro, Brazil.

11

12

13 *Corresponding author:

14 Professor Carlos Adam Conte Junior, D.V.M., M.Sc., Ph.D.

15 Rua Vital Brazil Filho, n. 64. Santa Rosa

16 Niterói – Rio de Janeiro, Brazil

17 CEP: 24.230-340

18 Phone: +55 21 – 2629-9545

19 E-mail address: carlosconte@id.uff.br (C.A. Conte Junior).

20

21

22

23

24

25 **Abstract**

26 Diarrhea in piglets is one of the main causes of animal death before and after weaning; In
27 recent decades, zinc oxide has been used in high doses to control this disease. These doses
28 are considered to be of concern for the pollutant potential of animal waste through soil and
29 groundwater pollution. New technologies such as nanotechnology, new matrices such as
30 biopolymers and encapsulation are suggestions that appear as possible innovations that can
31 minimize the challenges imposed by piglet weaning. This review aims to collect and
32 analyze information on novel zinc oxide products developed with innovative technologies.

33

34

35

36

37

38

39

40

41

42

43

44

45

46 **Introduction**47 ***The challenges of weaning piglets***

48 Modern pig industry is one of the most developed and technological sectors of
49 agribusiness, however the mortality of live-born piglets is still a major challenge, with no
50 significant advances in recent decades. Early weaning of piglets is the most critical stage of
51 production, the first weeks are particularly stressful and immunosuppressive for animals and
52 usually accompanied by delayed growth, weight loss, diarrhea and mortality (Lallès, 2007;
53 Lima, 2009; Campbell *et al.*, 2013; Sutherland *et al.*, 2014). The physical separation from the
54 sows and transition to a solid and complex diet, associated to an immature digestive tract,
55 resulting in intestinal structural damage characterized by lower intestinal villi height, greater
56 crypt depth and decreased intestinal enzymatic activity. Further the action of some pathogens,
57 such as *Escherichia coli* and rotavirus (Pluske *et al.*, 1997, Boudry *et al.*, 2004, Esquerre *et*
58 *al.*, 2011). *E. coli* is the most important factor for post-weaning diarrhea, also known as
59 colibacillosis (Fairbrother *et al.*, 2005, Heo, *et al.*, 2013).

60 The gastrointestinal disturbances cause large economic losses in the pig industry, the mortality
61 among piglets in the EU is approximately 17% and a significant part of these losses may be
62 associated with infections through mucosal surfaces (Lallès, 2007). In this context, many
63 studies have been developed in search of products that contribute to minimize the challenges
64 imposed by piglet weaning. This review aims to collect and analyze information on novel zinc
65 oxide (ZnO) products developed with innovative technologies such as nanoparticles,
66 encapsulation and use of biopolymers.

67

68 **Methodology**

69 This is a literature review of a systematic study of ZnO products for weaned piglets in
70 worldwide.


71

72 **Research Strategies**

73 Online scientific articles available at the Pubmed, Scielo, Science Direct, Google scholar
74 and Periodicals/CAPES databases, between 2015 and 2018, were selected. The evaluation of
75 the selected articles was divided into three stages. As an initial screening, in addition to the
76 term Zinc Oxide or ZnO, studies regarding nanotechnology and biopolymers, conducted in
77 animal nutrition.

78 After this initial screening, a second stage was performed based on the selected articles
79 describing the experiments performed with ZnO on weaned piglets. Finally, a third step
80 comprised the separation of results from *in vitro* and *in vivo* studies.

81 Check the stages of bibliographic research (identification, selection, eligibility and
82 inclusion of data) for literature review in Fig.1.



83

84 Figure 1: Stages of bibliographic research (identification, selection, eligibility and
85 inclusion of data) for literature review.

86

87 **ZnO as an additive to improve animal performance**

88 For decades, pharmacological doses of ZnO, up to 2,000 mg ZnO/kg, have been applied
89 to combat post-weaning diarrhea and to improve animal performance (Poulsen, 1995; Hollis
90 *et al.*, 2005; Pettigrew, 2006). Li *et al.* (2006) have observed that *in vitro* intestinal epithelial
91 regeneration capacity increases in the presence of exogenous ZnO and that there is an increase
92 in the level of intestinal insulin-like growth factor 1 (IGF-1 gene) in piglets fed with high
93 concentrations of ZnO (Li *et al.*, 2006). The IGF-1 gene is a hormone that regulates cell

94 growth and may contribute to intestinal tissue repair. Studies indicate that the ZnO promoter
95 effect occurs mainly in the first two weeks after weaning (Shelton *et al.*, 2009), in the same
96 period in which piglet intestinal adaptation is practically complete. Different studies have
97 shown that the inclusion of ZnO has effects on the increase of the gene expression of
98 antimicrobial peptides in the small intestine, with a positive action on the stability and
99 diversity of the microbiota, besides the reduction of the electrolyte secretion from enterocytes.
100 This association of events results in a bactericidal action (Pluske *et al.*, 2007; Zhang & Guo,
101 2009).

102

103 ***Antibacterial activity of ZnO***

104 The antibacterial activity of ZnO is scientifically grounded; however, the mechanisms by
105 which it modifies the gastrointestinal microbiota are not well elucidated. Roselli *et al.* (2003)
106 suggested that ZnO does not inhibit directly enteropathogenic *E. coli* growth, but rather the
107 ability of the microorganism to bind to intestinal cells. Concerning the efficacy of ZnO in
108 gram-positive and gram-negative bacteria, there are controversy results in the literature.
109 Vahjen *et al.* (2011) verified a greater susceptibility of gram-positive bacteria to ZnO, an
110 increase in the diversity of the species present in the intestine, besides the increase of
111 Enterobacteriaceae that would compete with enteropathogenic *E. coli* controlling its growth
112 indirectly. While Applerot (2009), Trandafilović *et al.* (2012) and Barreto *et al.* (2017) found
113 that gram-positive bacteria, such as *Staphylococcus aureus*, are more resistant to the action of
114 ZnO when compared to gram-negative, *E. coli*. The difference in antibacterial activity against
115 both microorganisms may be related to the different chemical and structural compositions of
116 cell membranes, particularly in the cell wall, in addition to the material used (Jones *et al.*,
117 2008; Shantikumar *et al.*, 2008; Xie *et al.*, 2011). According to Ann and Mahmoud (2014), *S.*
118 *aureus* tends to develop defenses against oxidative stress producing enzymes, such as

119 superoxide dismutase, catalase and thioredoxin reductase. Superoxide dismutase can convert
120 O_2 of H_2O_2 , catalase can convert H_2O_2 to H_2O and O_2 , and thioredoxin reductase can protect
121 the cell against toxic oxygen species (Ann and Mahmoud, 2014; Raghupathi *et al.*, 2011;
122 Ballal and Manna, 2010). In this way, *S. aureus* can construct an effective "shield" to reduce
123 the toxicity of ZnO samples. On the other hand, some ZnO particles may attach to the surface
124 of the bacterial membrane, and this mechanical damage could also be considered another
125 method of antimicrobial inhibition (Ann and Mahmoud, 2014).

126 High doses of ZnO altered intestinal microbial diversity in the ileum and colon of weaned
127 piglets and had comparable effects to antibiotics, especially affecting the non-predominant
128 microbiota population in ileum. Understanding the effects of high ZnO on intestinal bacterial
129 communities may provide information on the future application of the alternative strategy for
130 the treatment of diarrhea in piglets (Yu *et al.*, 2017).

131 ***Limitation associated with using ZnO as a performance enhancer***

132 ZnO is currently effective in improving performance and intestinal health in weaned
133 piglets at doses ranging from 2,000 to 4,000 mg Zn/kg of feed, which are considered to be of
134 concern for the pollutant potential of animal waste. These values are much higher than those
135 found in the *in vitro* tests, where minimum inhibitory concentrations (MIC) and bactericidal
136 (MBC) concentrations are often lower for different bacteria. In the literature there are MIC
137 and MBC results between 260 and 500 ppm for different strains of *E. coli* (Liedtke and
138 Vahjen, 2012; Barreto *et al.*, 2017). Studies indicate that the efficacy of ZnO for piglets is not
139 related to their absorption but to their action on the intestinal lumen, which consequently
140 causes a large part of the ingested Zn to be excreted via feces (Poulsen, 1995; Rincker *et al.*,
141 2005). Piglets supplemented with high levels of ZnO excrete between 60% and 80% of the
142 amount ingested, the higher the excretion being the higher the levels of Zn in the diet (Carlson
143 *et al.*, 2004).

144 The high level of Zn^{2+} excreted in feces is an environmental concern. Although Zn is
145 present in a relatively small amount, there is interest about the possible accumulation of this
146 metal in the environment (Gräber *et al.*, 2005). Zn is a necessary nutrient for the maintenance
147 and growth of plant tissues, but high concentrations in the soil can cause phytotoxicity (Zhang
148 *et al.*, 2012). Concern over the contamination of water by metals is even greater in artesian
149 well production systems or in farms close to rivers and lakes due to the low tolerance of
150 various species of fish to Zn toxicity (Gräber *et al.*, 2005; Zhang *et al.*, 2012). In addition,
151 fecal Zn is also a potential environmental inducer of bacterial resistance (Hölzel *et al.*, 2012;
152 Bednorz *et al.*, 2013; Yazdankhah *et al.*, 2014). In view of this, European legislation limits a
153 maximum of 150 mg Zn kg in pig diets (European Communities, 2003), dose well below the
154 pharmacological levels of ZnO reported as growth promoters for these animals.

155

156 ***ZnO Nanoparticles (ZnO Nano)***

157 Nanoparticulate ZnO is one of the most researched oxides due to its differentiated
158 physical, chemical and biological properties. Its low cost, versatility and availability make it
159 highly suitable for numerous industrial applications (Giraldi, *et al.*, 2012). According to the
160 literature, ZnO nanoparticles can be synthesized by different techniques, such as hydrothermal
161 (Suwanboon *et al.*, 2013), sol-gel (Muneer *et al.*, 2013), ultrasound (Khorsand *et al.*, 2013) of
162 precipitation (Chang *et al.*, 2008), among others. Nanoparticles are particles smaller than 100
163 nanometers (nm), in this way, ZnO nano has smaller particle size, larger number of particles
164 per unit mass and greater specific surface area compared to conventional ZnO microparticles
165 (Raghupathi *et al.*, 2011, Xie *et al.*, 2011), characteristics that make them more reactive in
166 chemical and biological systems. In addition, nanoparticles more easily cross biological
167 barriers such as the intestine (Buzea *et al.*, 2007).

168 Research on ZnO nanoparticles (Jones *et al.*, 2008, Xie *et al.*, 2011) indicates that the

169 surface effects of the molecule may also be responsible for its antibacterial action. The
170 interaction of the nanoparticles with the microorganisms, damaging the integrity of bacterial
171 cells (Zhang *et al.*, 2008) and the formation of reactive oxygen species (ROS) (Jalal *et al.*,
172 2010) are considered the main mechanisms. Jones *et al.* (2008) and Barreto *et al.* (2017)
173 suggest that ZnO nanoparticles have significant antibacterial effects on *S. aureus*.

174 The antibacterial effect of ZnO nanoparticles was investigated in *Campylobacter*
175 *jejuni* for inhibition and inactivation of cell growth. The results demonstrated that *C. jejuni*
176 was extremely sensitive to the treatment with ZnO nanoparticles and that the action of the
177 nanoparticles was bactericidal rather than bacteriostatic. According to the authors, the data
178 indicate that the antibacterial mechanism of the ZnO nanoparticles occurs due to the rupture of
179 the cell membrane and the cellular oxidative stress (Xie *et al.*, 2011). Nanoparticles of ZnO *in*
180 *vitro* exhibited strong antibacterial activity against *E. coli* in studies by Wang *et al.* (2012) and
181 Barreto *et al.* (2017), who believe that nanoparticles can damage the membrane and cause
182 lysis of bacterial cells. Studies have shown that ZnO nanoparticles may be potentially
183 antibacterial for the treatment of diseases caused by *E. coli*.

184 Minor particles of ZnO with larger contact surface with the gastrointestinal medium
185 seem to favor the effectiveness of ZnO as a growth promoter. In the literature, there are few
186 studies investigating the effects of ZnO nanoparticles on the zootechnical indexes of animals,
187 especially on swine. Nanoparticles of ZnO have been reported to increase growth
188 performance, improve power utility and provide benefits in weaned piglets (Yang and Sun,
189 2006), a study with piglets fed basal diets supplemented with 200, 400, 600 mg/kg of ZnO
190 nano or 3,000 mg/kg Zn showed encouraging average daily gain (Hongfu, 2008). On the other
191 hand, Li *et al.* (2016) and Milani *et al.* (2017) did not find concrete results of the effectiveness
192 of ZnO nanoparticles in piglets, but Milani *et al.* (2017) verified that ZnO nanoparticles
193 promoted a reduction in Zn excretion in feces of animals and, consequently, the environment.

194 Lina *et al.* (2009) in their study indicated that ZnO nano improved the performance
195 and production of broiler chickens at 42 days of feeding at the 40 mg/kg in the diet. The
196 supplementation of 20 to 60 mg of Zn/kg in the diet in the form of nanoparticulate ZnO
197 improved performance in broilers without presenting toxic or harmful effects when compared
198 to conventional ZnO (Ahmadi *et al.*, 2014; Zhao *et al.*, 2014). These authors observed higher
199 weight gain and better feed conversion in animals supplemented with ZnO nano compared to
200 conventional ZnO (Ahmadi *et al.*, 2013; Zhao *et al.*, 2014). According to Tsai *et al.* (2016),
201 ZnO nanoparticles for dietary supplementation of laying hens can increase Zn retention,
202 carbonic anhydrase enzyme activity, growth hormone and serum Zn level, and egg shell
203 thickness, proving that this nanometric oxide may increase Zn uptake in the intestine and have
204 positive effects when compared to ZnO conventionally used in laying diets.

205 Buentello *et al.* (2009) in their study reported that there are differences in the growth
206 rate in response to different dietary sources of Zn and different chemical substances Zn forms
207 showed differential bioavailability in fish. According to Tawfik *et al.* (2017) supplementation
208 of ZnO nanoparticles with fish feed may possibly improve the growth rates of these animals,
209 such as weight gain, specific growth rates and growth hormone in blood. This could be better
210 than conventional ZnO, so that it could be used in fish farms and aquaculture with their low
211 concentrations and this could improve the economy of aquiculture.

212 There are several researches focuses on investigating the toxicity of ZnO nanoparticles
213 in mices. It is known that doses above 500 and 1000 mg Zn/kg body weight cause small toxic
214 effects with elevated plasma Zn concentration, accumulation in kidneys, liver and lungs,
215 nephrotoxicity, respiratory tract inflammation and oxidative stress in cell membranes (Wang *et al.*
216 *et al.*, 2008; Yan *et al.*, 2012; Chung *et al.*, 2013; Hong *et al.*, 2014; Roy, *et al.*, 2015).

217 In recent years, the contribution of several researchers has increased in the
218 investigation of the antibacterial effect of ZnO nano, of the involved mechanisms, of safety,

219 and how its use can enable the reduction of the total amount of Zn needed to optimize the
220 results and, consequently, the polluting effect of the waste generated. Free ZnO nanoparticles,
221 structured or encapsulated in different matrices, appear as possible technological alternatives
222 in the use of ZnO as an additive for swine farming.

223

224 **Biopolymers**

225 *Polyelectrolytes and Complexes Polyelectrolytes (PEC)*

226 According to Canevarolo (2006), polymer is a word of greek origin composed of the
227 radical poly (many) and mere (unit of repetition). Polymers are macromolecules composed of
228 tens of thousands of repeating units and joined by covalent bonds. The monomers can be of
229 different types and present themselves in several combinations, they are the ones that
230 determine the length of the molecule and its molar mass (Canevarolo, 2006).

231 A polyelectrolyte is a polymer in which some groups of monomers along the chain
232 have ionic and/or ionizable groups (Hess *et al.*, 2006). In polar solution, the groups generally
233 ionize and acquire positive charge (polyactions), negative (polyanions) or both (polyphoton).
234 This feature gives polyelectrolytes the ability to interact strongly with macromolecules and
235 charged surfaces with opposing charges. Generally, they are quite hydrophilic, sensitive to pH
236 variation and the amount and types of electrolytes present in the solution (Lyklema, 2005).


237 The polyelectrolytes stand out for the ability to form interpolymer complexes, called
238 Polyelectrolyte Complexes (PECs) (Schatz *et al.*, 2004). The formation of PECs occurs
239 spontaneously by the simple mixing of oppositely charged polyelectrolytes with release of
240 counterions (Fig. 2).

241 The main force that leads to the formation of the PECs is the entropy gain caused by
242 the release of the low molar mass counterions. However, hydrogen bonds, hydrophobic
243 interactions and van der Waals forces, or the combination of these interactions, are important

244 in the formation of complexes (Dautzenberg, 2001).

245

246



247

248

249

250

Figure 2: Schematic representation of the formation of the PECs.

251

252

253

254

255

256

257

258

259

Because of their properties, the PECs have attracted interest for biotechnological, food and pharmaceutical applications such as protein immobilizers and drug carriers (Dautzenberg, 2001). The use of polymers in the synthesis of ZnO has been proposed by some authors as an interesting strategy to control the growth and agglomeration of nanoparticles. The chitosan (Murugadoss, Chattopadhyay, 2008, Shih, *et al*, 2009), the starch (Bozani'c *et al*, 2011; Raveendran *et al* 2003) and alginate (Gutowska *et al.*, 2001; Chang *et al.*, 2011) are particularly interesting as matrix polymers because their chains have a large number of hydroxyl groups that form complexes with the metal ions, for example Zn.

260

261

262

263

264

265

266

In addition to nanoparticle growth controllers, natural biopolymers are examples of materials that allow the development of capsules resistant to the upper gastrointestinal tract and release the encapsulated material into the intestinal environment, as verified by different authors (Braccini & Pérez, 2001; Chen & Subirade, 2005; Liu *et al.*, 2007; Jones & McClements, 2010; Patel *et al.*, 2011; Barreto *et al.*, 2017). In this sense, biopolymers are interesting as coatings or complexing materials with ZnO.


267 *Alginate*

268 Sodium alginate is a sodium salt of alginic acid, a water-soluble anionic polymer.
269 Alginic acid is a natural polysaccharide, extracted from brown seaweed, formed by β -D-
270 mannuronic acid (M) and α -L-guluronic acid (G) residues bound by binding (1 \rightarrow 4),
271 composition and sequence varied (Fig. 3). The ratio between these two units influences the
272 physical properties of this biopolymer (Lawrie *et al.*, 2007). The carboxylic acid groups on
273 these units assign negative charges to the alginate, making it capable of interacting
274 electrostatically with the positively charged molecules to form gels. The gels formed due to
275 the dimeric association of the G-G blocks in egg-box are induced by multivalent cation.

276 The alginate can be easily cross-linked with bivalent cations such as Ca^{2+} , Sr^{2+} , Zn^{2+} or
277 Ba^{2+} , among which Ca^{2+} is the most investigated (Luo & Wang, 2014). Alginate is
278 characterized by being biocompatible, hydrophilic, biodegradable under normal physiological
279 conditions and chemically stable at pH values between 5.0 and 10.0 (Sankalia *et al.*, 2007;
280 Saether *et al.*, 2008; Aelenei *et al.*, 2009). Alginate is one of the most widely used
281 biopolymers as a matrix for drug release, being abundant, easily manipulable, low cost and
282 interesting physicochemical properties (Liew, 2006).

283 Several authors have demonstrated the antimicrobial activity of different alginate
284 compositions and ZnO nanoparticles (Trandafilović *et al.*, 2012; Trandafilović *et al.*, 2014;
285 Chopra *et al.*, 2015; Cordero-Arias *et al.*, 2015; Karbowniczek *et al.*, 2017).

286



287

288


Figure 3: Sodium alginate chemical structure.

289

290 **Chitosan**

291 Chitosan is a biopolymer composed of repeating units of β -(1,4)-2-deoxy-2-amino-D-
292 glucose and is obtained from chitin by deacetylation in alkaline medium (Fig. 4) (Sharma,
293 2009; Shukla, 2013). In turn, chitin is a polysaccharide constituted by repetitive constitutional
294 units of β -(1,4)-2-deoxy-2-acetylamino-D-glucose (N-acetylglucosamine), abundantly found
295 in nature.

296



297

298

Figure 4: Chemical structure chitosan molecule.

299

300 The degree of deacetylation of chitosan ranges from 70 to 95% and the molar mass
301 between 10-1000 kDa (Hamman, 2010). Chitosan is a weak base with pKa values between
302 5.9-6.6 (Kumar *et al.*, 2004; Park *et al.*, 2010), and above this value its solubility is limited.
303 The amino groups present along the polymer chain act as cationic polyelectrolytes at pH <6.5
304 (George & Abraham, 2006). Therefore, chitosan is soluble in dilute weak acid solutions, such
305 as acetic acid (Laranjeira & Fávere, 2009). Thus, the cationic character of chitosan, acquired
306 in acid solution, by protonation of the amino groups, allows the electrostatic interaction with
307 specific polyanions and, consequently, the formation of intra- and intermolecular crosslinks.
308 However, as the pH is adjusted above 6.5, the amino groups become deprotonated and the
309 chitosan loses its charges, becoming insoluble (Dash *et al.*, 2011).

310 Chitosan presents, among other properties, biocompatibility, biodegradability,
311 antimicrobial activity and bioadhesiveness due to its polycationic nature. The number of
312 studies investigating chitosan as carrier and nanocarrier has increased significantly in the last
313 decades (Gan *et al.*, 2005; Boddohi *et al.*, 2009; Hamman, 2010; Dash *et al.*, 2011; Luo &
314 Wang, 2014). According to Laranjeira and Fávere (2009), the rate of drug release from
315 chitosan matrices is affected by the pH change. *In vitro* studies, simulating the gastrointestinal
316 tract, revealed that the dissolution profiles of these systems depend on the type of polymer
317 matrix and the pH of the simulated fluid (Laranjeira & Fávere, 2009).

318 Different methodologies can be used for the preparation of nano and microparticles
319 containing chitosan, which involve one or two types of association between macromolecules
320 (Tavares *et al.*, 2012). The formation of covalent crosslinking that requires a crosslinking
321 agent, such as glutaraldehyde, genipine and sodium tripolyphosphate (TPP) (Banerjee, *et al.*,
322 2002; Liu & Huang, 2008; Ocak, 2012) and the physical interaction, which involves methods
323 such as spray-drying, ionic gelling, reverse microemulsion, solvent evaporation/diffusion,
324 polyelectrolyte complexation and coacervation/precipitation (Harris *et al.*, 2011; Lee *et al.*,
325 2010; Mukhopadhyay *et al.* 2012).

326 In the literature, it is possible to verify that the complexation of chitosan with
327 polyanions such as pectin, collagen, xanthan gum, cellulose and sodium alginate has been
328 shown to be efficient in the development of formulations for drug delivery (Davidenko *et al.*,
329 2009; Plapied *et al.*, 2011). Alginate is often used in the formation of complexes with
330 chitosan, in addition to the complex formed remain biodegradable and biocompatible, it
331 becomes mechanically strong at low pH values where chitosan is soluble. While chitosan is
332 easily degraded by lysozymes, the chitosan-alginate complex has shown greater strength due
333 to the strong interaction between the polymer chains (Hamman, 2010). Several results have
334 been found on the use of chitosan and sodium alginate in the formation of micro and

335 nanoparticles by means of ionic interaction (Sarmiento *et al.*, 2006; Cafaggi *et al.*, 2007;
336 Sankalia *et al.*, 2007; Li *et al.*, 2008; Aelenei *et al.*, 2009; Lertsutthiwong *et al.*, 2009; Barreto
337 *et al.*, 2017).

338 Studies of the antibacterial activity of the nano complexed or chitosan coated ZnO
339 presented positive results regarding the control of gram positive and gram negative bacteria
340 (Bhadra *et al.*, 2011; Malini *et al.*, 2015; Vaseeharan *et al.*, 2015). Investigating Zn
341 nanoparticles encapsulated in biocompatible chitosan polymer, Bhadra *et al.* (2011) found that
342 the chitosan encapsulation helped to restrict the growth of the ZnO nanomaterial and that the
343 chitosan coated ZnO compound was bound to the external cell membrane of the bacteria
344 through the chitosan-NH₂. This increased the permeability of the cell membrane and resulted
345 in cell cytoplasm to leak the entire cell leading to destruction. The inhibition zone study
346 confirmed the highest antibacterial effect of chitosan-capped ZnO nanoparticles compared to
347 unencapsulated ZnO nanomaterial as well as chitosan against *E. coli* (Bhadra *et al.*, 2011). In
348 another study, the antibacterial activity of membranes synthesized with chitosan/ZnO
349 nanoparticles was investigated in *Klebsiella planticola* and *Bacillus subtilis*. In all cases, the
350 gram negative *K. planticola* was inhibited in a greater proportion compared to gram positive
351 *Bacillus subtilis* and according to the authors, the chitosan/ZnO nanocomposites appeared to
352 be very promising in relation to their antibacterial property (Malini *et al.*, 2015). Similarly,
353 antibacterial activity of chitosan-ZnO composite demonstrated the effective growth control as
354 gram negative *Vibrio parahaemolyticus* as gram positive *Bacillus lechiformis* bacteria
355 isolated from aquatic environments (Vaseeharan *et al.*, 2015).

356 In the literature, the application of complexes of ZnO and biopolymers in the animal
357 nutrition is not observed. In an *in vitro* study, Barreto *et al.* (2017) synthesized ZnO
358 nanoparticles complexed with chitosan and alginate polyelectrolytes with and without TPP.
359 The authors obtained compounds that showed a pronounced antibacterial effect against *E. coli*

360 and *S. aureus*, in addition to a release profile of the Zn^{2+} ions suitable for delivery to the
361 simulated enteric piglet environment, indicating that the polyelectrolyte complexes can
362 efficiently protect ZnO in the piglets' gastric environment (Barreto *et al.*, 2017).

363

364 ***Encapsulated ZnO***

365 The encapsulation of ZnO in different matrices has emerged as one of the alternatives
366 to protect the ZnO in the stomach and to allow the maximization of its release in the small
367 intestine.

368 In piglets, the addition of coated and microencapsulated zinc containing 100 g of
369 ZnO/kg of finished product, showed results equal to or greater than those of conventional
370 ZnO. Microencapsulated Zn is designed to provide ions (Zn^{2+}) in the ideal fraction of the
371 gastrointestinal tract resulting in maximum efficiency of control and treatment of post-
372 weaning diarrhea (Moran, 2007). Shen *et al.* (2014) found that a low concentration of coated
373 ZnO alleviated diarrhea in piglets and promoted intestinal development by protecting the
374 intestinal mucosa barrier from damage, stimulating the mucosal immune system and
375 regulating the intestinal microbiota, as well as high concentration of ZnO. In addition,
376 compared to a high concentration of ZnO, a low concentration of coated ZnO prevented
377 excessive accumulation of Zn in animals and reduced the Zn concentration of excreted feces
378 in order to achieve the goal of saving the Zn source and reducing the environmental pollution
379 of Zn (Shen *et al.*, 2014). However, Park *et al.* (2014) investigated the effects of lipid
380 encapsulated ZnO supplementation at a physiological level and the result was superior to that
381 of conventional ZnO at the same level in the weight gain of weaned piglets, but their effects
382 on suppression of diarrhea were lower than that of conventional ZnO. The results found by
383 Kim *et al.* (2015) indicated that dietary supplementation of 72 ppm of Zn as ZnO
384 encapsulated in lipids was as effective as that of 2,000 to 2,500 ppm Zn supplied as

385 conventional ZnO or antibiotics to improve growth performance, goblet cell density in the
 386 intestine, as well as reduction of diarrhea in challenged piglets with a low dose of *E. coli*
 387 (K88). The authors suggest that studies be performed under production conditions to
 388 determine the effects of lipid-coated ZnO over conventional ZnO in weaned piglets.
 389

390 Table 1: A brief overview of ZnO products and data found in vivo and in vitro assays.

References	Products	Results
Jones <i>et al.</i> (2008)	ZnO nano (50 - 70 nm)	Antibacterial activity: <i>Staphylococcus aureus</i>
Xie <i>et al.</i> (2011)	ZnO nano (50 nm)	Antibacterial activity: <i>Campylobacter jejuni</i>
Zhang <i>et al.</i> (2008)	ZnO nano (90-100 nm)	Antibacterial activity: <i>Escherichia coli</i>
Jalal <i>et al.</i> (2010)	ZnO nano (37-41 nm)	Antibacterial activity: <i>Escherichia coli</i>
Barreto <i>et al.</i> (2017)	ZnO nano (17 nm)	Antibacterial activity: <i>Escherichia coli</i> and <i>Staphylococcus aureus</i>
Wang <i>et al.</i> (2012)	ZnO nano (55-95 nm)	Antibacterial activity: <i>Escherichia coli</i>
Yang and Sun (2006)	ZnO nano (ND)	<i>In vivo</i> : Increase growth performance, improve power utility and provide benefits in weaned piglets.

Hongfu (2008)	ZnO nano (ND)	<i>In vivo</i> : Diarrhoea incidence reduced in piglets
Milani <i>et al.</i> (2017)	ZnO nano (31-108 nm)	<i>In vivo</i> : Weaning diarrhea control
Trandafilovi'c <i>et al.</i> (2012)	ZnO nano + Alginate (3.9 - 6.8 nm)	Antibacterial activity: <i>Staphylococcus aureus</i> and <i>Escherichia coli</i>
Trandafilovi'c <i>et al.</i> (2014)	ZnO nano + Alginate (100 nm)	Antibacterial activity: <i>Staphylococcus aureus</i> and <i>Escherichia coli</i>
Chopra <i>et al.</i> (2015)	ZnO nano + Alginate (75-80 nm)	Antibacterial activity: <i>Pseudomonas aeruginosa</i>
		High encapsulation efficiency
Cordero-Arias <i>et al.</i> (2015)	ZnO nano + Alginate (20-60 nm)	Antibacterial activity: <i>Escherichia coli</i>
Karbowniczek <i>et al.</i> (2017)	ZnO nano (40,8 nm) + Alginate + Chitosan	Antibacterial activity: <i>Salmonella enteric</i> and <i>Staphylococcus aureus</i>
Bhadra <i>et al.</i> (2011)	ZnO nano (80 nm) + Chitosan	Antibacterial activity: <i>Escherichia coli</i>

Malini et al. (2015)	ZnO nano + Chitosan	Antibacterial activity: <i>Klebsiella planticola</i> and <i>Bacillus substilis</i>
Vaseeharan et al. (2015)	ZnO nano (30 - 60 nm) + Chitosan	Antibacterial activity: <i>Vibrio parahaemolyticus</i> and <i>Bacillus lechiformis</i>
Barreto et al. (2017)	ZnO nano (17 nm) + Chitosan + Alginate	Antibacterial activity: Escherichia coli and Staphylococcus aureus
		<i>In vitro</i> : Optimum <i>in vitro</i> release profile of Zn ²⁺ in simulated enteric fluids assays.
Moran (2007)	Microencapsulated ZnO: Lipid matrix	<i>In vivo</i> : Maximum efficiency of control and treatment of post-weaning diarrhea
Shen et al. (2014)	Microencapsulated ZnO: Lipid matrix	<i>In vivo</i> : Reduced diarrhoea and reduced the Zn concentration of excreted faeces
Park et al. (2014)	Microencapsulated ZnO: Lipid matrix	<i>In vivo</i> : Weight gain of weaned piglets
Kim et al. (2015)	Microencapsulated ZnO: Lipid matrix	<i>In vivo</i> : Reduced plasma Zn concentration and faecal Zn excretion levels

391

392 **Considerations** ZnO is an important antimicrobial used to combat diarrhea common to
393 weaned piglets, its antimicrobial activity has been extensively researched and confirmed for
394 gram negative and gram positive bacteria. Elevated doses of ZnO have been shown to be
395 effective in the field; however, much is lost with animal waste, contaminating soils and

396 groundwater. In the last two decades, the interest has been increased by alternatives that
397 protect ZnO in the gastric environment and allow the maximization of its release in the enteric
398 environment. Novel knowledge such as nanotechnology and biopolymers as release matrices
399 arise bringing new perspectives to animal nutrition and to the challenges inherent in weaning
400 piglets.

401 However, scientific research on novel ZnO products, such as ZnO nanoparticles,
402 complexes ZnO/biopolymers, or ZnO encapsulated in animal nutrition, especially in pigs, is
403 still scarce. Further *in vitro* and *in vivo* studies are recommended for a better understanding of
404 the effect of ZnO nanoparticles, their location and mechanism of absorption, and the risk of
405 intoxication in animals. Adequate levels of ZnO in the diet should be focused in order to
406 minimize piglet mortality, confer better animal performance and economic benefits in a safe
407 way.

408

409 **References**

- 410 1. Aelenei, N.; Popa, M. I.; Novac, O.; Lisa, G.; Balaita, L. 2009. Tannic acid
411 incorporation in chitosan-based microparticles and *in vitro* controlled release. *Journal*
412 *of Material Science: Materia Medica*, 20:1095–1102.
- 413 2. Ahmadi, F., Ebrahimmezhad, Y., Sis, N.M., Ghalehkandi, J.G., 2013. The effects of
414 zinc oxide nanoparticles on performance, digestive organs and serum lipid
415 concentrations in broiler chickens during starter period. *Int. J. Biosci.* 3: 23-29.
- 416 3. Ahmadi, F., Ebrahimnezjad, Y., Ghalehkandi, J.G., Sis, N.M., 2014. The Effect of
417 Dietary Zinc Oxide Nanoparticles on the Antioxidant State and Serum Enzymes
418 Activity in Broiler Chickens During Starter. In: *International Conference on*
419 *Biological, Civil and Environmental Engineering*, 2014, Dubai, pp. 26-28.
- 420 4. Ann, L.C., Mahmud, S., Bakhori, S.K.M., Sirelkhatim, A., Mohamad, D., Hasan, H.,

- 421 *et al.* 2014. Antibacterial responses of zinc oxide structures against *Staphylococcus*
422 *aureus*, *Pseudomonas aeruginosa* and *Streptococcus pyogenes*. *Ceram. Int.*, 40: 2993-
423 3001.
- 424 5. Applerot, G. A., Lipovsky, R. Dror, N. Perkas, Y. Nitzan, R. Lubart, A. Gedanken,
425 2009. Enhanced antibacterial activity of nanocrystalline ZnO due to increased ROS-
426 mediated cell injury, *Advanced Functional Materials*, 19:842–852.
- 427 6. Ballal, A., A.C. Manna. 2010. Control of thioredoxinreductase gene (*trxB*)
428 transcription by SarA in *Staphylococcus aureus*. *Journal of Bacteriology*. 192:336–
429 345.
- 430 7. Banerjee, T.; Mitra, S.; Singh, A. K.; Sharma, R. K.; Maitra, A. 2002. Preparation,
431 characterization and biodistribution of ultrafine chitosan nanoparticles. *International*
432 *Journal of Pharmaceutics*, 243:93-105.
- 433 8. Barreto, M.S.R., Andrade, C.T., da Silva, L.C.R.P., Cabral, L.M., Paschoalin, V.M.F.,
434 Del Aguila, E.M. 2017. *In vitro* physiological and antibacterial characterization of
435 ZnO nanoparticle composites in simulated porcine gastric and enteric fluids. *BMC*
436 *Veterinary Research*, 13:181-191.
- 437 9. Bednorz, C.; Oelgeschläger, K.; Kinnemann, B.; Hartmann, S.; Neumann, K.; Pieper,
438 R.; Bethe, A.; Semmler, T.; Tedin, K.; Schierack, P.; Wieler, L.H.; Guenther, S. 2013.
439 The broader context of antibiotic resistance: Zinc feed supplementation of piglets
440 increases the proportion of multi-resistant *Escherichia coli* in vivo. *International*
441 *Journal of Medical Microbiology*, Jena, 303(6/7): 396-403.
- 442 10. Bhadra, P., Mitra, M.K., Das, G.C., Dey, R., Mukherjee, S. 2011. Interaction of
443 chitosan capped ZnO nanorods with *Escherichia coli*. *Materials Science and*
444 *Engineering C*, 31: 929–937.
- 445 11. Braccini, I; Pérez, S. 2001. Molecular basis of Ca²⁺-induced gelation in alginates and

- 446 pectins: the egg-box model revisited. *Biomacromolecules*, 2:1089-1096.
- 447 12. Boddohi, S., Moore, N., Patrick A. 2009. Johnson and Matt J. Kipper. Polysaccharide-
448 based polyelectrolyte complex nanoparticles from chitosan, heparin, and hyaluronan.
449 *Biomacromolecules*. 10:1402–1409.
- 450 13. Boudry, G., Péron V., Le Huërou-Luron I, Lallès, J.P., Sève, B. 2004. Weaning induces
451 both transient and long-lasting modifications of absorptive, secretory, and barrier
452 properties of piglet intestine. *J. Nutr.* 134(9):2256-62.
- 453 14. Bozani'c, D. K. B. 2011. Silver nanoparticles encapsulated in glycogen biopolymer:
454 Morphology, optical and antimicrobial properties. *Carbohydrate Polymers*, 83: 883–
455 890.
- 456 15. Buentello, J.A., Goff, J.B., Gatlin, D.M. 2009. Dietary Zinc Requirement of Hybrid
457 Striped Bass, *Morone chrysops*×*Morone saxatilis*, and Bioavailability of Two
458 Chemically Different Zinc Compounds, *Journal of the World Aquaculture Society*,
459 40(5): 687–694.
- 460 16. Buzea, C.; Blandino, I.I.P.; Robbie, K. 2007. Nanomaterials and nanoparticles:
461 Sources and toxicity. *Biointerphases*, New York, 2(4): MR17-MR172.
- 462 17. Cafaggi, S.; Russo, E.; Stefani, R.; Leardi, R.; Caviglioli, G.; Parodi, B.; Bignardi, A.;
463 De Toter, B.; Aiello, C.; Viale, M. 2007. Preparation and evaluation of nanoparticles
464 made of chitosan or N-trimethyl chitosan and a cisplatin–alginate complex. *Journal of*
465 *Controlled Release*, 121:110–123.
- 466 18. Campbell, J.M, Crenshaw, J.D., Polo, J., 2013. The biological stress of early weaned
467 piglets. *J. Anim. Sci. Biotechnol.* 4: 1-4.
- 468 19. Canevarolo, V. S. 2006. *Ciência dos Polímeros*, 2. ed. São Paulo, SP: Artliber Editora.
469 280p.
- 470 20. Carlson, M. S., C. A. Boren, C. Wu, C. E. Huntington, D. W. Bollinger, and T. L.

- 471 Veum. 2004. Evaluation of various inclusion rates of organic zinc either as a
472 polysaccharide or proteinate complex on the growth performance, plasma, and
473 excretion of nursery pigs. *J. Anim. Sci.* 82:1359–1366.
- 474 21. Chang, C.C., Ping L; Chun, H.L. 2008. Synthesis and characterization of nano-sized
475 ZnO powders by direct precipitation method. *Chemical Engineering Journal* 144:509–
476 513.
- 477 22. Chang, P.R., Yua, J., Ma, X., Anderson, D.P. 2011. Polysaccharides as stabilizers for
478 the synthesis of magnetic nanoparticles. *Carbohydrate Polymers*, 83: 640–644.
- 479 23. Chen, L.; Subirade, M. 2005. Chitosan/ [beta]-lactoglobulin core-shell nanoparticles as
480 nutraceutical carriers. *Biomaterials*, v. 26, n. 30, p. 6041-6053.
- 481 24. Chopra, M., Bernela, M., Kaur, P., Manuja, A., Kumar, B., Thakur, R. 2015.
482 Alginate/gum acacia bipolymeric nanohydrogels — Promising carrier for Zinc oxide
483 nanoparticles. *International Journal of Biological Macromolecules* 72: 827–833.
- 484 25. Chung, H.E.; Yu, J.; Baek, M.; Lee, J.A.; Kim, M.S.; Kim, S.H.; Maeng, E.H.; Lee,
485 J.K.; Jeong, J.; Choi, S.J. 2013. Toxicokinetics of zinc oxide nanoparticles in rats.
486 *Journal of Physics: Conference Series, Bristol*, 429: 12037-12045.
- 487 26. Cordero-Arias, L., Cabanas-Polo, S., Goudouri, O.M., Misra, S.K., Gilabert, J.,
488 Valsami-Jones, E., Sanchez, E., Virtanen, S., Boccaccini, A.R. 2015. Electrophoretic
489 deposition of ZnO/alginate and ZnO-bioactive glass/alginate composite coatings for
490 antimicrobial applications, *Materials Science & Engineering C*, 55:137– 144.
- 491 27. Dash, M., F. Chiellini, R. M. Ottenbriteb, E. Chiellini. 2011. Chitosan—A versatile
492 semisynthetic polymer in biomedical applications. *Progress in Polymer Science*,
493 36:981–1014.
- 494 28. Dautzenberg, H. 2001. Em: RADEVA. T. Physical chemistry of polyelectrolytes:
495 surfactant science series, v 99, New York: Marcel Dekker, 2001. 743.

- 496 29. Davidenko, N.; Blanco, M.D.; Peniche, C.; Bechera N, L.; Guerrero, S.; Tejero, J.M.
497 2009. Effects of Different Parameters on the Characteristics of Chitosan–Poly(acrylic
498 acid) nanoparticles obtained by the method of coacervation. *Journal of Applied*
499 *Polymer Science*, 111:2362–2371.
- 500 30. Esquerre R.G., Zhao J., Harrell R. 2011. Zinco e cobre como promotores de
501 crescimento para suínos. *Anais: IV Simpósio Brasil Sul de Suinocultura, Chapecó, SC*
502 – Brasil.
- 503 31. European Communities. Official Journal of the European Union. Commission
504 regulation (EC) n° 1334/2003 of 25 July 2003. Amending the conditions for
505 authorization of a number of additives in feeding stuffs belonging to the group of trace
506 elements, 2003. 6 p.
- 507 32. Fairbrother, J. M., Nadeau, E. & Gyles, C. L. 2005. *Escherichia coli* in postweaning
508 diarrhea in pigs: an update on bacterial types, pathogenesis, and prevention strategies.
509 *Anim Health Res Rev* 6:17–39.
- 510 33. Gräber, I.; Hansen, J.F.; Olesen, S.E.; Petersen, J.; Ostergaard, H.S.; Krogh, L. 2005.
511 Accumulation of Copper and Zinc in Danish Agricultural Soils in Intensive Pig
512 Production Areas. *Geografisk Tidsskrift - Danish Journal of Geography*, København,
513 105(2):15-22.
- 514 34. Gan, Q., T. Wang, C. Cochrane, P. McCarron. 2005. Modulation of surface charge,
515 particle size and morphological properties of chitosan–TPP nanoparticles intended for
516 gene delivery. *Colloids and Surfaces B: Biointerfaces*. 44:65–73.
- 517 35. George, M., T. E. Abraham. 2006. Polyionic hydrocolloids for the intestinal delivery
518 of protein drugs: alginate and chitosan – a review. *Journal of Controlled Release*,
519 114:1-14.
- 520 36. Giraldo, T. R., Santos, G. V. F., de Mendonca, V. R., Ribeiro, C., Weber, I.T. 2012.

- 521 Effect of synthesis parameters on the structural characteristics and photocatalytic
522 activity of ZnO. *Materials Chemistry and Physics*, 136:505–511.
- 523 37. Gutowska, A., Jeong, B., Jasionowski, M. 2001. Injectable gels for tissue engineering.
524 *The Anatomical Record*, 263:342–3499.
- 525 38. Hamman, J. H. 2010. Chitosan based polyelectrolyte complexes as potential carrier
526 materials in drug delivery systems. *Marine Drugs*, 8:1305-1322.
- 527 39. Harris, R.; Lecumberri, E.; Mateos-Aparicio, I.; Mengibar, M.; Heras, A. 2011.
528 Chitosan nanoparticles and microspheres for the encapsulation of natural antioxidants
529 extracted from *Ilex paraguariensis*. *Carbohydrate Polymers*, 84:803-806.
- 530 40. Hess, M.; Jones, R. G; Kahovec, J.; Kitayama, T.; Kratochvíl, P.; Kubisa, P.;
531 Mormann, W., Stepto, R.F.T., Tabak, D., Vohlídal, J., Wilks, E.S. 2006. Terminology
532 of polymers containing ionizable or ionic groups and of polymers containing ions
533 (IUPAC Recommendations 2006). *Pure and Applied Chemistry*, 78(11):2067-2074.
- 534 41. Heo, J. M., F. O. Opapeju, J. R. Pluske, J. C. Kim, D. J. Hampson, C. M. Nyachoti.
535 2013. Gastrointestinal health and function in weaned pigs: a review of feeding
536 strategies to control post-weaning diarrhea without using in-feed antimicrobial
537 compounds. *Journal of Animal Physiology and Animal Nutrition*, 97:207–237.
- 538 42. Hollis, G.R.; Carter, S.D.; Cline, T.R. Crenshaw, T.D., Cromwell, G.L., Hill, G.M.,
539 Kim, S.W., Lewis, A.J., Mahan, D.C., Miller, P.S., Stein, H.H., Veum, T.L 2005.
540 Effects of replacing pharmacological levels of dietary zinc oxide with copper dietary
541 levels of various organic zinc sources for weanling pigs. *Journal of Animal Science*,
542 83(9): 2123-2129.
- 543 43. Hölzel, C.S.; Müller, C.; Harms, K.S.; Mikolajewski, S.; Schäfer, S.; Schwaiger, K.;
544 Bauer, J. 2012. Heavy metals in liquid pig manure in light of bacterial antimicrobial
545 resistance. *Environmental Research*, New York, 113:21-27.

- 546 44. Hong, J.-S.; Park, M.-K.; Kim, M.-S.; Lim, J.-H.; Park, G.-J.; Maeng, E.-H.; Shin, J.-
547 H.; Kim, M.-K.; Jeong, J.; Park, J.-A.; Kim, J.-C.; Shin, H.-C. 2014. Prenatal
548 development toxicity study of zinc oxide nanoparticles in rats. *International Journal of*
549 *Nanomedicine*, Auckland, 9(2): 159-171.
- 550 45. Hongfu, Y.B.Z. 2008. Effects of Nano-ZnO on growth performance and diarrhea rate
551 in weaning piglets, *China Feed*, 1:08.
- 552 46. Jalal, R., Goharshadi, E.K., Abareshi, M., Moosavi, M., Yousefi, A., Nancarrow, P.
553 2010. ZnO nanofluids: green synthesis, characterization, and antibacterial activity.
554 *Materials Chemistry and Physics*, 121:198–201.
- 555 47. Jones, N., Ray, B., Koodali, T.R., Adhar, C.M. 2008. Antibacterial activity of ZnO
556 nanoparticle suspensions on a broad spectrum of microorganisms. *FEMS FEMS*
557 *Microbiology Letters*, 279:71-76.
- 558 48. Jones, O. G.; McClements, D. J. 2010. Functional Biopolymer Particles: Design,
559 Fabrication, and Applications. *Comprehensive Reviews in Food Science and Food*
560 *Safety*, 9(4):374-397.
- 561 49. Karbowniczek, J., Cordero-Arias, L., Virtanen, S., Misra, S.K., Valsami-Jones, E.,
562 Rutkowski, B., Górecki, K., Bała, P., Czyrska-Filemonowicz, A., Boccaccini, A.R.
563 2017. Electrophoretic deposition of organic/inorganic composite coatings containing
564 ZnO nanoparticles exhibiting antibacterial properties. *Materials Science &*
565 *Engineering C*, doi: 10.1016/j.msec.2017.03.180.
- 566 50. Khorsand Zak, A; Majid, W.H; Wang, H.Z; Yousefi, R; Moradi Golsheikh, A; Ren,
567 Z.F. 2013. Sonochemical synthesis of hierarchical ZnO nanostructures, *Ultrasonics*
568 *Sonochemistry*, 20:395–400.
- 569 51. Kim, S.J., Chang, H.K., Park, B.C., Lee, C.Y., Han, J.H. 2015. Effects of a lipid-
570 encapsulated zinc oxide dietary supplement, on growth parameters and intestinal

- 571 morphology in weanling pigs artificially infected with enterotoxigenic *Escherichia*
572 *coli*. *Journal of Animal Science and Technology*, 57:4.
- 573 52. Kumar, B.; Sandhu, K.; Kaur, I. 2004. Topical 0.25% methotrexate gel in a hydrogel
574 base for palmoplantar psoriasis. *Journal of Dermatology*, 31:798-801.
- 575 53. Lallès, J., Bosi, P., Smidt, H., Stokes, C.R., 2007. Weaning-a challenge to gut
576 physiologists. *Livest. Sci.* 108:82-93.
- 577 54. Laranjeira, M.C.M. & Fávere, V.T. 2009. Quitosana: biopolímero funcional com
578 potencial industrial biomédico. *Química Nova*, 32:672-678.
- 579 55. Lawrie, G.; Keen, I.; Drew, B.; Chandler-Temple, A.; Rintoul, L.; Fredericks, P.;
580 Grøndahl, L. 2007. Interactions between Alginate and Chitosan Biopolymers
581 Characterized Using FTIR and XPS. *Biomacromolecules*, 8:2533-254.
- 582 56. Lee, E. J.; Khan, S. A.; Kim, Y. B.; Lim, K. H. 2010. Preparation of
583 chitosan/carboxymethyl dextran nanoparticles by polyelectrolyte complexation.
584 *Journal of Biotechnology*, 150:450-451.
- 585 57. Lertsutthiwong, P.; Rojsitthisak, P.; Nimmannit, U. 2009. Preparation of turmeric oil-
586 loaded chitosan-alginate biopolymeric nanocapsules. *Materials Science and*
587 *Engineering C*, 29:856–860.
- 588 58. Li, M.Z., Huang, J.T., Tsai, Y.H., Mao, S.Y., Fu, C.M., Lien, T.F., 2016. Nanosize of
589 zinc oxide and the effects on zinc digestibility, growth performances, immune
590 response and serum parameters of weanling piglets. *Anim. Sci. J.* 87:1379-1385.
- 591 59. Li, P.; Dai, Y.; Zhang, J.; Wang, A.; Wei, Q. 2008. Chitosan–Alginate Nanoparticles as
592 a Novel Drug Delivery System for Nifedipine. *International Journal of Biomedical*
593 *Science*, 4: 221-228.
- 594 60. Li X, Yin J, Li D, Chen X, Zang J, Zhou X. 2006. Dietary supplementation with zinc
595 oxide increases IGF-I and IGF-I receptor gene expression in the small intestine of

- 596 weanling piglets. *The Journal of Nutrition*, 136:1786–1791.
- 597 61. Liedtke, J., Vahjen, W. 2012. In vitro antibacterial activity of zinc oxide on a broad
598 range of reference strains of intestinal origin. *Veterinary Microbiology*, 160: 251–255.
- 599 62. Liew, C.V.; Chan, L.W.; Ching, A.L.; Heng, P.W. 2006. Evaluation of sodium alginate
600 as drug release modifier in matrix tablets. *International Journal of Pharmaceutics*,
601 309:25-37.
- 602 63. Lima G.J.M.M., Mores N. & Sanches R.L. 2009. As diarréias nutricionais na
603 suinocultura. *Acta Scientiae Veterinariae*, 37:17-30.
- 604 64. Lina, T., Jianyang, J., Fenghua, Z., Huiying, R. and Wenli, L. 2009. Effect of nano-
605 zinc oxide on the production and dressing performance of broiler. *Chinese Agricultural*
606 *Science Bulletin*, 2: 003.
- 607 65. Liu, B. S. & Huang, T. B. 2008. Nanocomposites of genipin-crosslinked
608 chitosan/silver nanoparticles - structural reinforcement and antimicrobial properties.
609 *Macromolecular Bioscience*, 8:932.
- 610 66. Liu, L.; Fishman, M.; Hicks, K. 2007. Pectin in controlled drug delivery – a review.
611 *Cellulose*, 14(1):15-24.
- 612 67. Luo, Y. and Q. Wang. 2014. Recent development of chitosan-based polyelectrolyte
613 complexes with natural polysaccharides for drug delivery. *International Journal of*
614 *Biological Macromolecules*, 64:353–367.
- 615 68. Lyklema, J. The bottom size of colloids. 2005. *Bulletin of the Polish Academy of*
616 *Sciences Technical Sciences*, 53:317-323.
- 617 69. Malini, M., Thirumavalavan, M., Yang, W.Y., Lee, J.F., Annadurai, G. 2015. A
618 versatile chitosan/ZnO nanocomposite with enhanced antimicrobial properties.
619 *International Journal of Biological Macromolecules* 80: 121–129.
- 620 70. Milani, N.C., Sbardella, M. Ikeda, N.Y., Arno, A., Mascarenhas, B.C., Miyada, V.S.

- 621 2017. Dietary zinc oxide nanoparticles as growth promoter for weanling pigs, *Animal*
622 *Feed Science and Technology* <http://dx.doi.org/10.1016/j.anifeedsci.2017.03.001>.
- 623 71. Moran, C. 2007. Designing a new growth promoter in the 21st century. In: J.Patterson
624 (ed.) *Australasian Pig Science Association*, p. 159-169. *Manipulating pig production*
625 XI, Werribee, Vic. Australia.
- 626 72. Mukhopadhyay, P.; Mishra, R.; Rana, D.; Kundu, P. 2012. Strategies for effective oral
627 insulin delivery with modified chitosan nanoparticles: A review. *Progress in Polymer*
628 *Science*, 37:1457–1475.
- 629 73. Muneer, M., Ba-Abbad, Abdul Amir H., Kadhum, Mohamad, A.B., Mohd S. Takriff,
630 Kamaruzzaman Sopian. 2013. The effect of process parameters on the size of ZnO
631 nanoparticles synthesized via the sol–gel technique. *Journal of Alloys and*
632 *Compounds*, 550:63–70.
- 633 74. Murugadoss, A., Chattopadhyay, A. 2008. A ‘green’ chitosan–silver nanoparticle
634 composite as a heterogeneous as well as micro-heterogeneous catalyst.
635 *Nanotechnology*, 19: 015603 doi: 10.1088/0957-4484/19/01/015603.
- 636 75. Ocak, B. 2012. Complex coacervation of collagen hydrolysate extracted from leather
637 solid wastes and chitosan for controlled release of lavender oil. *Journal of*
638 *Environmental Management*, 100: 22-28
- 639 76. Park, J. H., Saravanakumar, G., Kim, K., Kwon, I. C. 2010. Targeted delivery of low
640 molecular drugs using chitosan and its derivatives. *Advanced Drug Delivery Reviews*,
641 63:28-41.
- 642 77. Park, B.C., Jung, D.Y., Kang, S.Y., Ko, Y.H., Ha, D.M., Kwonc, C.H., Park, M.J.,
643 Hanc, J.H., Jang, I., Lee, C.Y. 2014. Effects of dietary supplementation of a zinc oxide
644 product encapsulated with lipid on growth performance, intestinal morphology, and
645 digestive enzyme activities in weanling pigs. *Animal Feed Science and Technology*,

- 646 200:112-115.
- 647 78. Patel, K.R.; Patel, M.R.; Mehta, T.J.; Patel, A.D.; Patel, N.M. 2011.
- 648 Microencapsulation: Review on novel approaches. *International Journal of Pharmacy*
- 649 *and Technology*, 3:894-911.
- 650 79. Pettigrew, J.E. 2006. Reduced use of antibiotic growth promoters in diets fed to
- 651 weanling pigs: Dietary tools, part 1. *Animal Biotechnology*, 17:207–215.
- 652 80. Plapied, L.; Duhem, N.; Rieux, A.; Pr at, V. 2011. Fate of polymeric nanocarriers for
- 653 oral drug delivery. *Current Opinion in Colloid & Interface Science*, 16:228–237.
- 654 81. Pluske, J.R.; Hampson, D.J.; Williams, I.H. 1997. Factors influencing the structure and
- 655 function of the small intestine in the weaned pig: a review. *Livestock Production*
- 656 *Science*, Amsterdam, 51(1/3): 215-236.
- 657 82. Pluske, J.R., Hansen, C.F., Payne, H.G., Mullan, B.P., Kim, J.-C. and Hampson, D.J.
- 658 2007. Gut health in the pig. In *Manipulating Pig Production XI* (J.E. Paterson and J.A.
- 659 Barker, eds.), pp. 147-158. Australasian Pig Science Association, Werribee, Victoria,
- 660 Australia.
- 661 83. Poulsen, H.D. 1995. Zinc Oxide for Weanling Piglets. *Journal Acta Agriculturae*
- 662 *Scandinavica A*, 45(3): 159-167.
- 663 84. Raghupathi, K.R., R.T. Koodali, A.C. Manna. 2011. Size-dependent bacterial growth
- 664 inhibition and mechanism of antibacterial activity of zinc oxide nanoparticles,
- 665 *Langmuir* 27:4020–4028.
- 666 85. Raveendran, P., Fu, J., Wallen, S. L. 2003. Completely green synthesis and
- 667 stabilization of metal nanoparticles. *Journal of the American Chemical Society*,
- 668 125:13940–13941.
- 669 86. Rincker, M.J.; Hill, G.M.; Link, J.E.; Meyer, A.M.; Rowntree, J.E. 2005. Effects of
- 670 dietary zinc and iron supplementation on mineral excretion, body composition, and

- 671 mineral status of nursery pigs. *Journal of Animal Science*, Champaign, 83(12): 2762-
672 2774.
- 673 87. Roy, R.; Das, M.; Dwivedi, P.D. 2015. Toxicological mode of action of ZnO
674 nanoparticles: Impact on immune cells. *Molecular Immunology*, Oxford, 63(9): 184-
675 192.
- 676 88. Roselli, M., Finamore A., Garaguso I., Britti M.S. & Mengheri E. 2003. Zinc oxide
677 protects cultured enterocytes from the damage induced by *Escherichia coli*. *Journal of*
678 *Nutrition*. 133:4077-4082.
- 679 89. Saether, H.V.; Holme, H.K.; Maurstad, G.; Smidsrød, O.; Bjørn, T.; Stokke, H. 2008.
680 Polyelectrolyte complex formation using alginate and chitosan. *Carbohydrate*
681 *Polymers*, 74:813–821.
- 682 90. Sankalia, M.G.; Mashru, R.C.; Sankalia, J.M.; Sutariya, V.B. 2007. Reversed chitosan–
683 alginate polyelectrolyte complex for stability improvement of alpha-amylase:
684 Optimization and physicochemical characterization. *European Journal of*
685 *Pharmaceutics and Biopharmaceutics*, 65: 215–232.
- 686 91. Sarmiento, B.; Ferreira, D.; Veiga, B.; Ribeiro, A. 2006. Characterization of insulin-
687 loaded alginate nanoparticles produced by ionotropic pre-gelation through DSC and
688 FTIR studies. *Carbohydrate Polymers*, 66:1–7.
- 689 92. Schatz, C., Domard, A., Viton, C., Pichot, C., Delai, T. 2004. Versatile and efficient
690 formation of colloids of biopolymer-based polyelectrolyte complexes.
691 *Biomacromolecules*, 5:1882-1892.
- 692 93. Shantikumar N., S. Abhilash, V. V. Divya, M. Deepthy, N. Seema, K Manzoor Satish.
693 2008. Antibacterial activity of zinc oxide nanoparticles. *African Journal of*
694 *Microbiology Research*, 24: 465-471.
- 695 94. Sharma, S., Soni, V.P., Bellare, J.R. 2009. Chitosan reinforced apatite–wollastonite

- 696 coating by electrophoretic deposition on titanium implants. *Journal of Materials*
697 *Science. Materials in Medicine*, 20:1427–1436.
- 698 95. Shelton, N. W.; Derouchev, J. M.; Neill, C. R.; Tokach, M. D.; Dritz, S. S.; Goodband,
699 R. D.; Nelssen, J. L. 2009. Effects of increasing feeding level during late gestation on
700 sow and litter performance. In: *SWINE DAY. Report of progress*. Kansas State
701 University, p 38-50.
- 702 96. Shen, J. H., Chen, Y., Wang, Z., Zhou, A.G, He, M., Mao, L., Zou, H., Peng, Q., Xue,
703 B., Wang, L., Zhang, X., Wu, S., Lv, Y. 2014. Coated zinc oxide improves intestinal
704 immunity function and regulates microbiota composition in weaned piglets. *Br. J.*
705 *Nutr.* 111: 2123–2134.
- 706 97. Shih, C.-M., Shieh, Y.-T., e Twu, Y.-K. 2009. Preparation of gold nanopowders and
707 nanoparticles using chitosan suspensions. *Carbohydrate Polymers*, 78:309–315.
- 708 98. Shukla, S. K. 2013. Chitosan-based nanomaterials: A state-of-the-art review.
709 *International Journal of Biological Macromolecules*, 59:46-58.
- 710 99. Sutherland, M.A., Backus, B.L. and McGlone, J.J. 2014. Effects of Transport at
711 Weaning on the Behavior, Physiology and Performance of Pigs. *Animals* 4:657-669.
- 712 100. Suwanboon, S., Amornpitoksuk, P., Bangrak, P., Randorn, C. 2013. Physical
713 and chemical properties of multifunctional ZnO nanostructures prepared by
714 precipitation and hydrothermal methods. *Ceramics International*, 40: 975-983.
- 715 101. Tawfik M.M.M, Moustafa M.M., Abumourad I.M.K., El-Meliegy EM, Refai
716 M.K. 2017. Evaluation of Nano Zinc Oxide feed additive on tilapia Growth and
717 Immunity, 15th International Conference on Environmental Science and Technology
718 Rhodes, Greece, 31 August to 2 September 2017.
- 719 102. Tavares, I. S.; Caroni, C.; Dantas Neto, A.; Pereira, M. R.; Fonseca, J. 2012.
720 Surface charging and dimensions of chitosan coacervated nanoparticles. *Colloids and*

- 721 Surfaces B: Biointerfaces, 90: 254 – 258.
- 722 103. Trandafilovi'c, L.V., Whiffen, R.K., Dimitrijevi'c –Brankovi'c, S., Stoiljkovi'c,
723 M., Luyt, A.S., Djokovic, V. 2014. ZnO/Ag hybrid nanocubes in alginate biopolymer:
724 Synthesis and properties. Chemical Engineering Journal 253: 341–349.
- 725 104. Trandafilovi'c, L.V.; Božani'c, D.K; Dimitrijevi'c-Brankovi'c, S.; Luyt, a.S.;
726 Djokovi'c, V. 2012. Fabrication and antibacterial properties of ZnO–alginate
727 nanocomposites. Carbohydrate Polymers, 88:263-269.
- 728 105. Tsai, Y.H., Mao, S.Y., Li, M.Z., Huang, J.T., Lien, T.F., 2016. Effects of
729 nanosize zinc oxide on zinc retention, eggshell quality, immune response and serum
730 parameters of aged laying hens. Anim. Feed Sci. Technol. 213:99-107.
- 731 106. Vahjen, W., Pieper, R., Zentek, J. 2011. Increased dietary zinc oxide changes the
732 bacterial core and enterobacterial composition in the ileum of piglets. Journal of
733 Animal Science, 89:240–243.
- 734 107. Vaseeharan, B., Sivakamavalli, J., Thaya, R. 2015. Synthesis and
735 characterization of chitosan-ZnO composite and its antibiofilm activity against aquatic
736 bacteria. Journal of Composite Materials, 49(2):177-184.
- 737 108. Wang, B., Feng, W., Wang, M., Wang, T., Gu, Y., Zhu, M., Ouyang, H., Shi, J.,
738 Zhang, F., Zhao, Y., Chai, Z., Wang, H., Wang, J. 2008. Acute toxicological impact of
739 Nano and submicro-scaled zinc oxide powder on healthy adult mice, J Nanopart Res,
740 10:263-76.
- 741 109. Wang, C.; Liu, L.-L.; Zhang, A.-T.; Xie, P.; Lu, J.-J.; Zou, X.-T. 2012yang.
742 African Journal of Biotechnology, Nairobi, 11(44): 10248-10254.
- 743 110. Yan, G.; Huang, Y.; Bu, Q.; LV, L.; Deng, P.; Zhou, J.; Wang, Y.; Yang, Y.; Liu,
744 Q.; Cen, X.; Zhao, Y. 2012. Zinc oxide nanoparticles cause nephrotoxicity and kidney
745 metabolism alterations in rats. Journal of Environmental Science and Health - Part A,

- 746 Toxic/hazardous substances & environmental engineering, New York, 47(4):577-588.
- 747 111. Yang, Z.P. and Sun, L.P. 2006. Effects of nanometre ZnO on growth
748 performance of early weaned piglets. *J. Shanxi Agric. Sci.*, 3: 024.
- 749 112. Yazdankhah, S.; Rudi, K.; Bernhoft, A. 2014. Zinc and copper in animal
750 feeddevelopment of resistance and co-resistance to antimicrobial agents in bacteria of
751 animal origin. *Microbial Ecology in Health and Disease*, Chichester, 25: 1-7.
- 752 113. Yu, T., Zhu, C., Chen, S., Gao, L., Lv, H., Feng, R., Zhu, Q., Xu, J., Chen, Z.,
753 Jiang, Z. (2017). Dietary High Zinc Oxide Modulates the Microbiome of Ileum and
754 Colon in Weaned Piglets. *Frontiers in Microbiology*, 8, 825.
- 755 114. Xie, Y., Y. He, P. L. Irwin, T. Jin, X. Shi. 2011. Antibacterial activity and
756 mechanism of action of zinc oxide nanoparticles against *Campylobacter jejuni*.
757 *Applied and Environmental Microbiology*, 77: 2325–2331.
- 758 115. Zhang, L; Y. Ding, M. Povey, D. York. 2008. ZnO nanofluids – A potential
759 antibacterial agent, *Progress in Natural Science*, 18:939-944.
- 760 116. Zhang, B and Guo, Y. 2009. Supplemental zinc reduced intestinal permeability
761 by enhancing occluding and zonula occludens protein 1 (ZO-1) expression in weaning
762 piglets. *British Journal of Nutrition* 102:687-693.
- 763 117. Zhang, F.S., Li, Y.X., Yang, M., Li, W. 2012. Content of heavy metals in animal
764 feeds and manures from farms of different scales in northeast China. *Int. J. Environ.*
765 *Res. Pub. Health* 9:2658–2668.
- 766 118. Zhao, Y.C., Shu, T.X., Xiao, Y.X., Qiu, S.X., Pan, Q.J., Tang, X.Z., 2014.
767 Effects of dietary zinc oxide nanoparticles on growth performance and antioxidative
768 status in broiler. *Biol. Trace Elem. Res.* 160, 361-367.